Transplantation and Cellular Therapy Meetings | Conference

Dr. Lulla Discusses Post-Transplant Options for Leukemias

February 24th 2019

Premal Lulla, MD, discusses the need for cellular therapies for patients with leukemia after transplant.

Dr. Giralt on Allogeneic HCT in Multiple Myeloma

February 23rd 2019

Sergio A. Giralt, MD, discusses the role of allogeneic hematopoietic cell therapy in patients with multiple myeloma.

Dr. Dandoy on TMA Risk After Pediatric Allogeneic Stem Cell Transplant

February 23rd 2019

Christopher E. Dandoy, MD, MSc, says that patients undergoing allogenic stem cell transplant are at high-risk of developing thrombotic microangiopathy.

Elevated Levels of ST2 and sC5b-9 Potentially Predictive of Thrombotic Microangiopathy

February 23rd 2019

Christopher E. Dandoy, MD, MSc, discussed how higher levels of soluble suppression of tumorigenicity-2 and soluble terminal complement complex were associated with high-risk thrombotic microangiopathy, a severe complication related to stem cell transplantation.

Thrombotic Microangiopathy a Threat After Hematopoietic Cell Transplant

February 23rd 2019

Transplant-associated thrombotic microangiopathy occurred in as many as 36% of hematopoietic cell transplants and significantly increased the risk of transplant-related mortality.

Dr. Champlin on the Role of EASIX Following Allogeneic Stem Cell Transplant

February 23rd 2019

Richard E. Champlin, MD, a professor of medicine at MD Anderson Cancer Center, discusses the association seen between the Endothelial Activation and Stress Index (EASIX) and fluid overload and survival in patients who underwent an allogenic stem cell transplantation.

Dr. Kumar on Utility of ASCT in Newly Diagnosed Multiple Myeloma

February 22nd 2019

Shaji Kumar, MD, of Mayo Clinic, advises physicians on the use of autologous stem cell transplant in patients with newly diagnosed multiple myeloma.

Locke Covers AE Management Linked With CAR T-Cell Therapies

February 22nd 2019

Frederick L. Locke, MD, discusses the optimal management of chimeric antigen receptor T-cell therapy-related adverse events.

Ibrutinib Plus CAR T-Cell Therapy Boosts Response in CLL

February 22nd 2019

Patients with relapsed/refractory chronic lymphocytic leukemia had an improved response rate with chimeric antigen receptor T-cell therapy if they also received ibrutinib.

Pretransplant MRD Prognostic for Outcomes in Adults With ALL

February 22nd 2019

Adults with acute lymphoblastic leukemia had worse outcomes, including lower survival, after myeloablative allogeneic transplantation if they remained positive for minimal residual disease at the time of transplant.

Expert Highlights Encouraging PFS Data With Maintenance Ixazomib in Multiple Myeloma

February 21st 2019

Gareth Morgan, MD, discusses the TOURMALINE-MM3 findings in multiple myeloma and other clinical trials that are impacting the landscape for this patient population.

Axicabtagene Ciloleucel Shows Response Rate of 76% in Aggressive Lymphoma

February 27th 2017

Axicabtagene ciloleucel had an objective response rate of 76% and a complete response rate of 47% in patients with aggressive non-Hodgkin lymphoma followed for at least 1 month.

Prophylactic Letermovir Limits CMV Infections Post-Transplantation

February 27th 2017

Prophylactic treatment with letermovir lowered the rates of cytomegalovirus infection and all-cause mortality compared with placebo for CMV-seropositive patients following an allogeneic hematopoietic stem cell transplant.

Vorinostat Lowers Acute GVHD in Patients Receiving Unrelated Donor HSCT

February 26th 2017

Vorinostat combined with tacrolimus and methotrexate represents a potentially effective combination to mitigate graft-versus-host disease in the setting of matched unrelated donor myeloablative conditioning hematopoietic stem cell transplant.

Dr. Marty on Letermovir for CMV Prevention After Stem Cell Transplant

February 26th 2017

Francisco Marty, MD, Dana-Farber Cancer Institute, discusses the initial results of the Phase III trial evaluating letermovir for CMV after bone marrow transplant.

Nursing Coordination Invaluable to Successful Delivery of CAR T Therapy

February 26th 2017

Proper care coordination and patient education are essential to the success of delivering chimeric antigen receptor T-cell therapy, particularly in preparing patients for potential adverse events.

New and Emerging Approaches Target the Immunologic Chaos of GVHD

February 26th 2017

A host of new and emerging therapies for acute and chronic graft-versus-host disease are on the horizon and include B-cell depletion, IL-2, inhibitors of JAK1/JAK2, extracorporeal photopheresis, and the BTK inhibitor ibrutinib.

Novel Pretransplant Conditioning Regimens Seek to Reduce Relapse in Blood Cancers

February 26th 2017

Sergio A. Giralt, MD, reviewed emerging strategies to improve stem cell transplantation outcomes by reducing the risk of relapse using novel drugs and targeted radiotherapy.

Dr. Locke on the ZUMA-1 Trial of KTE-C19 for Lymphoma

February 26th 2017

Fred Locke, MD, Moffitt Cancer Center discusses the interim results of the ZUMA-I trial of Kte-C19, a CAR T-cell therapy.

Dr. Scott on Conditioning Regimens for Stem Cell Transplants

February 26th 2017

Bart Scott, MD, Fred Hutchinson Cancer Research Center, explains the importance of the intensity of conditioning for stem cell transplants.